171 related articles for article (PubMed ID: 12752030)
1. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.
Søholm B; Lublin H
Acta Psychiatr Scand; 2003 May; 107(5):344-50. PubMed ID: 12752030
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Ramasubbu R; Ravindran A; Lapierre Y
Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
[TBL] [Abstract][Full Text] [Related]
3. [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].
Jarema M; Olajossy M; Chrzanowski W; Araszkiewicz A; Landowski J; Rybakowski J; Bilikiewicz A; Bomba J; Debowska G
Psychiatr Pol; 2003; 37(4):641-55. PubMed ID: 14560493
[TBL] [Abstract][Full Text] [Related]
4. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
5. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
7. [Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Hilger E; Kasper S
Wien Klin Wochenschr; 2000 Dec; 112(24):1031-8. PubMed ID: 11204312
[TBL] [Abstract][Full Text] [Related]
8. Comparable dopamine 2 receptor occupancy.
de Haan L; van Amelsvoort T
Am J Psychiatry; 2002 Dec; 159(12):2118; author reply 2118-9. PubMed ID: 12450982
[No Abstract] [Full Text] [Related]
9. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
10. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine. Keep an eye on this neuroleptic.
Can Fam Physician; 2000 Feb; 46():322-6, 330-6. PubMed ID: 10690489
[TBL] [Abstract][Full Text] [Related]
12. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
[TBL] [Abstract][Full Text] [Related]
13. [Olanzapine in the first episode of schizophrenia in young adults].
Dabkowska M
Psychiatr Pol; 2002; 36(6 Suppl):235-41. PubMed ID: 12647444
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
Miller DS; Yatham LN; Lam RW
J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
[TBL] [Abstract][Full Text] [Related]
15. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Gothelf D; Apter A; Reidman J; Brand-Gothelf A; Bloch Y; Gal G; Kikinzon L; Tyano S; Weizman R; Ratzoni G
J Neural Transm (Vienna); 2003 May; 110(5):545-60. PubMed ID: 12721815
[TBL] [Abstract][Full Text] [Related]
17. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
[TBL] [Abstract][Full Text] [Related]
18. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
Weimer E; Braus DF; Cavus I; Thome J
Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436
[TBL] [Abstract][Full Text] [Related]
19. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
20. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
Ho BC; Miller D; Nopoulos P; Andreasen NC
J Clin Psychiatry; 1999 Oct; 60(10):658-63. PubMed ID: 10549681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
